Evidence map›Paper›PMID 22659219›Full record

ArticleJournal of proteomics2012

Phosphoprotein abundance changes in hypertensive cardiac remodeling.

Kumar Kotlo, Keven R Johnson, Jean M Grillon, David L Geenen, Pieter deTombe, Robert S Danziger

Abstract read
In one paragraph

Article in Journal of proteomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 34 citations in OpenAlex.

  1. Proteomics of the heart.Physiological reviews · 2024
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. PP2A as a master regulator of the cell cycle.Critical reviews in biochemistry and molecular biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Kumar KotloDepartment of Medicine, University of Illinois at Chicago, 840 South Wood Street, Chicago, IL 60612, USA.
Keven R Johnson
Jean M Grillon
David L Geenen
Pieter deTombe
Robert S Danziger
University of Illinois Chicago · USJesse Brown VA Medical Center · USLoyola University Chicago · US

Funding

Sarcomeric Modifications and Progressive Cardiac MaladaptationP01HL062426 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI AI, XUN · 2000 to 2020
$42.4M
TRAINING IN CELLULAR SIGNALLING IN THE CARDIOVASCULAR SYT32HL007692 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SOLARO, R JOHN · 1990 to 2014
$8.5M
Functional Interaction of ANP and NO signalingK01DK071641 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KOTLO, KUMAR U · 2006 to 2010
$746k
Phosphoprotein Signaling In Experimental Cardiac RemodelingR21HL096031 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DANZIGER, ROBERT S · 2010 to 2011
$437k
NHLBI NIH HHS P01 HL062426NHLBI NIH HHS R21 HL096031NHLBI NIH HHS R21HL096031NHLBI NIH HHS T32 HL007692NHLBI NIH HHS T32 HL 07692NIDDK NIH HHS K01 DK071641NIDDK NIH HHS KO1 DK071641
6 · The paper itself

Abstract

There is over-whelming evidence that protein phosphorylations regulate cardiac function and remodeling. A wide variety of protein kinases, e.g., phosphoinositide 3-kinase (PI3K), Akt, GSK-3, TGFβ, and PKA, MAPKs, PKC, Erks, and Jaks, as well as phosphatases, e.g., phosphatase I (PP1) and calcineurin, control cardiomyocyte growth and contractility. In the present work, we used global phosphoprotein profiling to identify phosphorylated proteins associated with pressure overload (PO) cardiac hypertrophy and heart failure. Phosphoproteins from hypertrophic and systolic failing hearts from male hypertensive Dahl salt-sensitive rats, trans-aortic banded (TAC), and spontaneously hypertensive heart failure (SHHF) rats were analyzed. Profiling was performed by 2-dimensional difference in gel electrophoresis (2D-DIGE) on phospho-enriched proteins. A total of 25 common phosphoproteins with differences in abundance in (1) the 3 hypertrophic and/or (2) the 2 systolic failure heart models were identified (CI>99%) by matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) and Mascot analysis. Among these were (1) myofilament proteins, including alpha-tropomyosin and myosin regulatory light chain 2, cap Z interacting protein (cap ZIP), and tubulin β5; (2) mitochondrial proteins, including pyruvate dehydrogenase α, branch chain ketoacid dehydrogenase E1, and mitochondrial creatine kinase; (3) phosphatases, including protein phosphatase 2A and protein phosphatase 1 regulatory subunit; and (4) other proteins including proteosome subunits α type 3 and β type 7, and eukaryotic translation initiation factor 1A (eIF1A). The results include previously described and novel phosphoproteins in cardiac hypertrophy and systolic failure.

Indexed as

Ventricular RemodelingAnimalsCardiomegalyHeart FailureHypertensionMuscle ProteinsMyocardiumMyocytes, CardiacPhosphoproteinsRatsRats, Inbred SHRRats, WistarSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationMuscle ProteinsPhosphoproteins

Identifiers

PMID22659219
PMCPMC3581302
OpenAlexW1989065404

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.